Navigation Links
Boston Scientific Announces Clinical Data Supporting Safety and Efficacy of Platinum Chromium PROMUS Element™ Stent
Date:9/21/2010

e PROMUS Stent to the PROMUS Element Stent," said Keith D. Dawkins, M.D., Senior Vice President and Chief Medical Officer for Boston Scientific's Cardiology, Rhythm and Vascular Group.  "The PLATINUM QCA results further support the performance of the everolimus drug/polymer combination while demonstrating a highly effective platinum chromium PROMUS Element Stent platform.  The PROMUS Element Stent also demonstrates an excellent safety profile in this study with only a single patient experiencing a cardiac event within 30 days and no additional events through nine months."  

"We are extremely pleased with the positive safety and efficacy results of the PLATINUM QCA study, which reinforce the overall benefits provided by our new platinum chromium stent platform," said Hank Kucheman, Executive Vice President and President of Boston Scientific's Cardiology, Rhythm and Vascular Group.  "These favorable outcomes for our everolimus-eluting PROMUS Element Stent, together with the recent European launch of our paclitaxel-eluting TAXUS® Element™ Stent, illustrate our unparalleled pipeline of drug-eluting stent technologies."

The Company expects U.S. Food and Drug Administration approval for the TAXUS Element Stent System (3) in mid 2011 and for the PROMUS Element Stent System in mid 2012.  In Japan, the Company expects approval for the TAXUS Element Stent System in late 2011 or early 2012 and for the PROMUS Element Stent System in mid 2012.

The randomized, controlled PLATINUM Workhorse clinical trial completed enrollment in September 2009 with 1,531 patients at more than 130 sites worldwide and compares the PROMUS Element Everolimus-Eluting Coronary Stent System to the PROMUS (Xience V) Everolimus-Eluting Coronary Stent System.  One-year data from the trial will be presented at the Scientific Session of the American College of Cardiology/i2 Summit in March 2011.  

In the U.S., the PROMUS Element and TAX
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. Boston University Biomedical Engineers Find Chink in Bacterias Armor
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- Market Research ... Industry, 2009-2019 is a professional and in-depth market ... Scanner industry . The report firstly reviews the ... classification, application and manufacturing technology. The report then ... Crystallography Scanner listing their product specification, capacity, Production ...
(Date:8/29/2014)... 2014 The clinical and medical insights provided ... between a product,s success or failure. Despite this, many ... targets – and then to coordinate activities and outreach ... upon which successful KOL engagement rests. ... internal inconsistencies in their KOL management systems and are ...
(Date:8/29/2014)... /PRNewswire-iReach/ -- SAM Medical Products Implements Voluntary Recall ... Junctional Tourniquet.  Photo - ... announced today that it has begun notifying customers ... issue with a clip used to secure the ... the SAM Junctional Tourniquet (SJT).  The company discovered ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5Implementing a Strategic Thought Leader Management & Engagement System 2SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2
... to Phase 3; Eligible for Accelerated Approval; ... Global Regulatory Plan Expected by Year End, CRANBURY, ... a biopharmaceutical company developing small molecule,orally-administered pharmacological chaperones for ... has successfully completed an End,of Phase 2 meeting for ...
... Rare Genetic Disorder in,Children--, PHILADELPHIA, July 31 ... levels of blood sugar in animals genetically,engineered to ... in humans, it could become an innovative medicine ... devastating genetic,disease in which insulin levels become dangerously ...
Cached Medicine Technology:Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease 2Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease 3Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease 4Treatment Corrects Severe Insulin Imbalance in Animal Studies 2Treatment Corrects Severe Insulin Imbalance in Animal Studies 3
(Date:9/2/2014)... 02, 2014 The Quantum Group, ... Quantum Innovations, Inc . (QI), it has submitted ... MU2 Certification with a private IT security laboratory approved ... The platform has Meaningful Use 1 certification status (see ... approved and 15 pending patents. The accrediting organization has ...
(Date:9/2/2014)... public support for marijuana legalization in the U.S. has ... than other substances, such as alcohol. In January, President ... marijuana is more dangerous than alcohol. Despite the recent ... as compared to alcohol use are not well understood. ... Outcomes Associated with Drug Use among US High School ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 At the ... Prosupps will be an exhibitor at the Las ... Rd, Las Vegas, NV 89109 Booth #374 Sept 19th ... to encourage healthy living through exercise, diet and supplementation. ... vision, and provide the tools for all Prosupps customers ...
(Date:9/2/2014)... Smile Squared, a well-known Buy One, Give ... a US-made toothbrush. For every toothbrush purchased, Smile Squared ... Squared was created by my wife and me after ... Cope, President of Smile Squared. “There, we saw children ... many of the same children didn't own a toothbrush. ...
(Date:9/2/2014)... Tuesday 2 September 2014: Digoxin may increase the ... by approximately 20%, according to results from the ROCKET ... Manesh Patel, director of interventional cardiology and catheterisation labs ... US. The findings suggest that caution may be needed ... studies are needed to confirm the observations. , Dr ...
Breaking Medicine News(10 mins):Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 2Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 3Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 4Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 5Health News:NYU study compares consequences of teen alcohol and marijuana use 2Health News:NYU study compares consequences of teen alcohol and marijuana use 3Health News:Prosupps, One of the Fastest Growing Supplement Companies, Celebrates a Success Milestone with Exhibiting at the 50th Annual 2014 Mr. Olympia’s Fitness & Performance Expo 2Health News:Smile Squared's Colorful Buy One, Give One Toothbrush Now Available in Schnucks Stores 2Health News:ROCKET AF trial suggests that digoxin increases risk of death in AF patients 2
... MISSISSAUGA, ON, May 13 /PRNewswire-FirstCall/ - Cipher Pharmaceuticals,Inc. ... Drug Application (NDA),has been submitted to the U.S. ... extended-release formulation of tramadol. In May 2007,the Company ... to its,NDA for CIP-TRAMADOL ER., Cipher,s revised ...
... May 13 Lumenis Inc., a global,developer, ... radiofrequency,devices for surgical, aesthetic, and ophthalmic applications, ... Enucleation of the Prostate (HoLEP),preceptor program that ... interested in learning and performing HoLEP. The ...
... Project proceeds despite non-compliance with California Environmental ... Quality ... Center (PHCMC) today went ahead with the planned expansion of its,Holy ... has upheld charges that the approval process was significantly flawed.,The groundbreaking ...
... 12 /PRNewswire-FirstCall/ - Med-Emerg International Inc.,(OTCBB - MDER), ... three months ended March 31, 2008 were $5.5 ... in 2007 (all amounts are $US unless,otherwise stated). ... interest and taxes (EBITDA) improved to $179K,from a ...
... TSX:,WHT) World Heart Corporation ("WorldHeart" or the "Corporation") ... Bulletin today advising it,is reviewing the eligibility for ... of WorldHeart under sections 709 and 710(a) of ... Company,s financial condition and,operating results, more specifically whether ...
... Institute (KGI),today announced that the May 17, 2008, commencement ... Applied Life Sciences student, Eric,Tan, and the unveiling of ... and proud of Eric,s achievement in becoming the,first graduate ... KGI,s senior,vice president for academic affairs, dean of faculty ...
Cached Medicine News:Health News:Cipher provides regulatory update for CIP-TRAMADOL ER 2Health News:Cipher provides regulatory update for CIP-TRAMADOL ER 3Health News:Lumenis Launches HoLEP Preceptor Program at American Urology Association 2008 Annual Meeting 2Health News:Lumenis Launches HoLEP Preceptor Program at American Urology Association 2008 Annual Meeting 3Health News:Providence Holy Cross Medical Center Ignores Community, Environmental Concerns With Planned Expansion of Mission Hills Facility 2Health News:Med-Emerg International Inc. reports improved income from continuing operations 2Health News:Med-Emerg International Inc. reports improved income from continuing operations 3Health News:WorldHeart Notified of TSX Delisting Review 2Health News:KGI 2008 Commencement Features First PhD Graduate, Biotech Painting 2
... The ImmunoWELL VZV IgG ... for the qualitative detection of ... (VZV). Test results are used ... status or infection. Immune status ...
... Test is an enzyme immunoassay (EIA) test ... human thyroglobulin and human thyroid peroxidase (microsome) ... is used as an aid in the ... disorders are characterized by detection of anti-thyroid ...
... ImmunoDOT Autoimmunity Screening Panel 1 is ... screening and detection of autoantibodies against ... SS-A/SS-B, RNP/Sm) in serum, and is ... diagnosis of systemic lupus erythematosus (SLE), ...
... Antibody (IgG) Test is an ... quantitative detection of antibodies to ... is used as an aid ... thrombosis in individuals with systemic ...
Medicine Products: